Digital Neurology: Overcoming the Blood-Brain Barrier to Combat Glioblastoma

The collaboration between Snke and Precision NeuroMed marks a paradigm shift in neuro-oncology, leveraging cloud-based digital infrastructure to master the delivery of precision medicine for previously untreatable brain tumors.

June 16, 2026 | Reported by Electronics Medical

In a development that could redefine the clinical management of the most aggressive forms of brain cancer, Munich-based healthtech company Snke—a subsidiary of the surgical technology leader Brainlab—has announced a strategic technology partnership with California-based biotech firm Precision NeuroMed (PNM). The initiative aims to build a robust digital backbone for "Convection-Enhanced Delivery" (CED), a sophisticated method designed to bypass the blood-brain barrier and deliver therapeutic agents directly into brain tissue.

For patients diagnosed with glioblastoma, the most aggressive primary brain tumor in adults, the standard of care—comprising surgical resection, radiation, and chemotherapy—has remained stagnant for decades. With a prognosis that often remains grim, the medical community has long awaited a breakthrough that addresses the fundamental hurdle of neuro-oncology: the blood-brain barrier. By integrating cloud-native workflow orchestration with advanced medical hardware, Snke and PNM are moving from theoretical research toward a scalable, data-driven reality for CNS (Central Nervous System) therapy.

The Core Challenge: Penetrating the Blood-Brain Barrier

The human brain is protected by a sophisticated biological defense mechanism: the blood-brain barrier (BBB). While essential for preventing harmful substances in the bloodstream from entering the delicate neural environment, the BBB is a formidable adversary for oncologists. Traditional systemic chemotherapy is frequently blocked by this barrier, meaning that even high doses of potent anti-cancer drugs often fail to achieve sufficient concentrations within a tumor site to be effective.

Precision NeuroMed (PNM) is addressing this challenge through Convection-Enhanced Delivery (CED). Unlike intravenous delivery, CED utilizes computer-guided microcatheters to infuse therapeutic agents directly into the interstitial space of the tumor and surrounding tissue. By applying a pressure gradient, the method allows for a uniform distribution of the drug across a larger target volume than simple injection, effectively "bypassing" the BBB entirely. However, the success of CED is highly dependent on extreme precision—the catheter must be placed with sub-millimeter accuracy, and the infusion parameters must be meticulously controlled to ensure patient safety.

Chronology of Innovation

The partnership between Snke and PNM did not emerge in a vacuum. It represents the culmination of years of iterative progress in both medical software and biotechnology:

• Pre-2025: Brainlab, the parent company of Snke, invests heavily in digital infrastructure, surgical navigation, and AI-assisted planning tools.
• 2025: Snke is spun off from Brainlab as an independent entity, dedicated to building a digital ecosystem that integrates healthcare IT, simulation, and data science for clinical environments.
• February 2026: Precision NeuroMed enters an initial collaboration with Brainlab to develop AI-supported planning software specifically for the CED procedure.
• June 2026: The partnership expands to include Snke, which will provide its proprietary cloud-based "Cockpits" platform to manage the clinical workflow, data exchange, and multi-institutional collaboration required for the rollout of PNM’s therapy candidates, including the FDA-Orphan-Drug-designated PNM-201.

Supporting Data and Technical Framework

The success of this partnership hinges on the "platform logic" provided by Snke. The Snke Cockpits platform serves as a central nervous system for the clinical team, consolidating diverse data streams into a unified, user-friendly interface.

The Role of the Digital Cockpit

The workflow for a CED procedure involves complex neuro-imaging, surgical planning, and post-operative monitoring. Snke’s platform facilitates:

1. Case Coordination: Streamlining communication between neurosurgeons, oncologists, and radiologists.
2. Structured Data Collection: Automatically aggregating Real-World Evidence (RWE) from imaging and treatment logs.
3. Institutional Interoperability: Allowing findings from one clinical center to inform the practices of others, creating a shared knowledge base for rare, high-stakes procedures.

By creating a clinical register that maps image data to patient outcomes, the partners aim to shorten the "learning loop." In medicine, the time it takes for a new technique to be refined—based on successes and complications—is often measured in years. Through this digital infrastructure, the companies expect to accelerate these cycles, enabling clinicians to optimize the infusion process far more rapidly than traditional methods would allow.

Official Perspectives: Bridging Anatomy and Digital Workflow

The collaboration represents a marriage of biology and informatics. Executives from both firms emphasize that the future of neurology is not merely about identifying the right molecule, but about the precision with which that molecule is deployed.

Stefan Vilsmeier, Founder and CEO of Snke:

"Precision therapies require precision workflows. With Snke Cockpits, we are creating the digital backbone that connects clinicians, experts, and data, while keeping the patient firmly at the center of the process. It is about removing the friction from the clinical environment so that the focus remains on the therapeutic outcome."

Dr. Sandeep Kunwar, Founder and CEO of Precision NeuroMed:

"Developing advanced CNS therapies is not just a question of anatomy or pharmacology. The true challenge lies in the coordination of complex data and the commitment to continuous improvement. By partnering with Snke, we are ensuring that our breakthrough CED method is supported by an infrastructure that makes it scalable, repeatable, and ultimately more effective for the patients who need it most."

Strategic Implications for the Future of Oncology

The implications of this partnership extend far beyond the treatment of glioblastoma. If the Snke-PNM model proves successful, it could provide a blueprint for treating a wide array of neurological conditions that have historically been considered "inaccessible," such as neurodegenerative diseases or complex pediatric brain tumors.

1. Scaling "Orphan" Treatments

By using digital tools to standardize a highly specialized procedure, the partners are effectively lowering the barrier to entry for hospitals worldwide. If a procedure requires a "digital cockpit" to ensure safety, then hospitals equipped with this software can potentially offer high-level neuro-oncological care, rather than centralizing all treatment in a few elite global centers.

2. The Era of Real-World Evidence

The creation of a systematic clinical register is a significant step toward "Precision Medicine 2.0." Instead of relying solely on controlled clinical trials, the medical community will have access to a continuous stream of real-world data. This allows for the rapid identification of subtle patterns—such as which specific tumor microenvironments respond best to certain infusion pressures—leading to hyper-personalized treatment protocols.

3. A Digital Ecosystem

The partnership confirms a growing trend: the "silo" era of medicine is ending. By connecting the biotechnology (PNM-201) with the surgical planning (Brainlab) and the clinical workflow management (Snke), the companies are building a vertical ecosystem. This integration minimizes the risk of human error during the high-stakes transition from planning a tumor resection to delivering a drug into the brain.

Conclusion: The Path Forward

The collaboration between Snke and Precision NeuroMed is a testament to the fact that the future of cancer treatment is as much about software as it is about chemistry. While the road to curing glioblastoma remains difficult, the integration of cloud-based workflow orchestration and direct-delivery technology represents one of the most promising technological leaps in modern neurology. As the companies move into the next phase of their clinical register development, the medical community will be watching closely to see if this "digital backbone" can indeed turn the tide against the most challenging tumors known to medicine.

About the Partners

Snke
Based in Munich, Snke is a healthtech innovator born from the Brainlab ecosystem. With over 350 specialists in data science, medical imaging, and software engineering, the company focuses on creating a data-driven infrastructure for modern healthcare. Their presence in Munich, Chicago, Heidelberg, and Tel Aviv positions them at the intersection of global medical innovation.
www.snke.com

Precision NeuroMed (PNM)
Headquartered in Redwood City, California, PNM is a biotechnology firm dedicated to modifying the course of severe neurological diseases. Their focus is exclusively on the brain, utilizing proprietary CED technology to overcome the blood-brain barrier. Their lead candidate, PNM-201, has received Orphan Drug status from the FDA, reflecting the urgent need for new solutions in neuro-oncology.
www.precisionneuromed.com